PA-EXONE
1.9.2021 14:32:06 CEST | Business Wire | Press release
The ExOne Company (Nasdaq: XONE), the global leader in industrial sand and metal 3D printers using binder jetting technology, and the Fraunhofer Institute for Manufacturing Technology and Advanced Materials (“Fraunhofer IFAM”), one of the most important independent research institutions in Europe, today announced they are deepening their partnership on binder and materials development projects following the success of CleanFuse™ metal binder.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210901005493/en/
Fraunhofer IFAM’s relationship with ExOne on metal binder jetting development spans more than two decades. They have been working together since about 1998, when ExOne, then part of Extrude Hone, launched the world’s first commercial metal binder jetting system, the RTS-300. In recent years, they have jointly refined and optimized CleanFuse, an ExOne binder based on a development by Fraunhofer IFAM. The result is a clean-burning binder for optimal 3D printing of stainless steels and premium metals.
“When we started developing the first binder version on the Innovent, we soon realized we had a major breakthrough. ExOne was immediately very enthusiastic about our development, because of its exceptional green part strength and clean burnout at low curing temperature. Together with ExOne, we refined the binder, which is now CleanFuse,” says Prof. Frank Petzoldt, Deputy Director of Fraunhofer IFAM since 1999.
Following this success, Fraunhofer IFAM and ExOne have decided to intensify their cooperation and are currently working on a CleanFuse version for processing reactive materials such as aluminum and titanium.
“At ExOne, we truly believe in the power of collaboration – of bringing together a diversity of experts and knowledge – to solve complex problems in the best possible way,” said Rick Lucas, ExOne Chief Technology Officer and VP, New Markets. “Fraunhofer IFAM has been a leading collaboration partner for us – helping to improve our understanding of binders, different types of powders, and how they work together through the entire process chain from printing to final sintering to deliver a quality part.”
Fraunhofer IFAM has a strong foundation in the development and processing of metallic and polymer materials as well as comprehensive knowledge of additive manufacturing technologies – especially for sinter-based processes. The institute’s location in Bremen is fully equipped for sinter-based additive manufacturing and offers all technologies for the printing, depowdering, debinding and sintering of metal parts. The researchers have special know-how around metal powders, binders and their interaction. For research and development in the field of metal binder jetting, they work with a range of ExOne printers starting with the Innovent+ for material and process development. Three printers feature ExOne’s patented Triple Advanced Compaction Technology (ACT) delivering industry- leading green part density. Recently, the institute has put the X1 25Pro® production-speed metal binder jetting system into operation in order to investigate feasibility in context of pilot and pre-series production. Manufacturers interested in metal binder jetting are welcome to schedule a visit to Fraunhofer IFAM Bremen to learn more about the technology and the application possibilities in their fields.
http://www.ifam.fraunhofer.de/de/Presse/Downloads.html
About Fraunhofer IFAM
The Fraunhofer IFAM is one of the most important independent research institutions in Europe for adhesive bonding technology, surfaces, shaping and functional materials. Research and development primarily address industries with special significance for future viability: aviation, automotive, energy technology, medical technology and life sciences, and maritime technologies. At our institute’s five locations – Bremen, Dresden, Stade, Wolfsburg and Braunschweig – as well as at the Test Center for Maritime Technologies on Helgoland – we put our central principles into practice: scientific excellence, a focus on the application of technology, measurable utility at the highest quality for customers. www.ifam.fraunhofer.de
About ExOne
ExOne is the pioneer and global leader in binder jet 3D printing technology. Since 1995, we’ve been on a mission to deliver powerful 3D printers that solve the toughest problems and enable world-changing innovations. Our 3D printing systems quickly transform powder materials — including metals, ceramics, composites and sand — into precision parts, metalcasting molds and cores, and innovative tooling solutions. Industrial customers use our technology to save time and money, reduce waste, improve their manufacturing flexibility, and deliver designs and products that were once impossible.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210901005493/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 12:00:00 CEST | Press release
Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubru
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
